People · Operator
Named in public records as an officer, director or promoter · active 2013–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bilayer Therapeutics, Inc. | — | Biotechnology | Seed | $2.3M | $2.4M | 2021 |
| Phrixus Pharmaceuticals Inc | — | Pharmaceuticals | Pre-Seed | $100K | $4.7M | 2013 |
Thomas A. Collet at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas A. Collet on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carlo Giovanni Traverso | 1 | 6 |
| Robert A. Langer | 1 | 3 |
| Huang Giovanni Yen-Chen | 1 | 1 |
| David Giovanni Zhu | 1 | 1 |
| Carlo Traverso Giovanni | 1 | 1 |
| Leslie A Browne | 1 | 1 |
| Gerald A Brennan | 1 | 1 |
| Bruce A Markham | 1 | 1 |
| Joshua A. Korzenik | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.